» Articles » PMID: 30114390

Fos-like Antigen 2 (FOSL2) Promotes Metastasis in Colon Cancer

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 2018 Aug 17
PMID 30114390
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Among different cancers, incidence and mortality of colorectal cancer (CRC) is one of the highest. KRAS mutation is one of the underlying features in the pathogenesis of CRC with CRC tumors harboring mutant KRAS exhibiting a more aggressive behavior compared to CRC tumors with wild type KRAS. We had earlier shown that the microRNA-143 (miR-143) replenishment not only chemosensitizers CRC cell line with mutant KRAS instead of wild-type KRAS gene, to paclitaxel-mediated cytotoxicity, but also inhibits cell migration and invasion ability. Hence, the study aimed to determine how miR-143 replenishment is inhibiting pre-metastatic behavior in CRC cells with mutant KRAS. Top ten mRNA targets of miR-143 as predicted by TargetScan were evaluated by qRT-PCR in LoVo cells which were performed mock transfection or miR-143 mimic transfection. Evaluation of the changes in cognate mRNA target(s) was done in 30 paired CRC tissue and tumor adjacent normal tissue specimens and in LoVo cells by western blot. Effect of the mRNA target on pro-metastatic behavior was assayed by gain- and loss-of-function studies using a combination of western blotting and in vitro cell proliferation and transwell migration/invasion assay in LoVo cells and in the normal colonic epithelium cell line FHC. In vivo effect of the cognate mRNA target on CRC metastasis was assayed by xenograft assay. Of the 10 predicted mRNA targets, FOSL2 (P < 0.05) and IGFBP5 (P > 0.05) was down regulated in LoVo cells transfected with the miR-143 mimic. FOSL2 mRNA levels were significantly downregulated in CRC tissue specimens compared with adjacent normal tissue (P < 0.05). Immunoblot analysis showed that FOSL2, but not IGFBP5, protein expression is down regulated in LoVo cells after the miR-143 mimic transfection. FOSL2 overexpression in the normal colonic epithelial cell line FHC or siRNA-mediated silencing in LoVo cells induced and repressed, respectively, pro-mesenchymal cell features. Whereas manipulation of FOSL2 expression did not have any effect on cell proliferation rates, silencing its expression inhibited cell migration and invasion ability in vitro. In addition, silencing of FOSL2 expression in the LoVo cells can significantly inhibited invasion of hepatic, while no effect was found for tumorigenic potential. Our results suggest that FOSL2 is a critical regulator of CRC metastasis and might be an important marker for prognostic in CRC patients.

Citing Articles

Non-cell autonomous regulation of cell-cell signaling and differentiation by mitochondrial ROS.

Du Y, Wang L, Perez-Castro L, Conacci-Sorrell M, Sieber M J Cell Biol. 2024; 223(12.

PMID: 39535785 PMC: 11561560. DOI: 10.1083/jcb.202401084.


Bioinformatic and experimental data pertaining to the role of the NLRP3 inflammasome in ovarian cancer.

Ashmore A, Balasubramanian B, Phillips A, Asher V, Bali A, Ordonez-Moran P J Cancer Res Clin Oncol. 2024; 150(11):488.

PMID: 39516433 PMC: 11549120. DOI: 10.1007/s00432-024-05988-9.


Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy.

Zhu S, Zhu W, Zhao K, Yu J, Lu W, Zhou R Cell Commun Signal. 2024; 22(1):361.

PMID: 39010083 PMC: 11247895. DOI: 10.1186/s12964-024-01733-4.


Progress in the Study of Fra-2 in Respiratory Diseases.

Zheng S, Liu Y Int J Mol Sci. 2024; 25(13).

PMID: 39000247 PMC: 11240912. DOI: 10.3390/ijms25137143.


Circ_0005615 Regulates the Progression of Colorectal Cancer Through the miR-873-5p/FOSL2 Signaling Pathway.

Yu L, Zhang F, Wang Y Biochem Genet. 2023; 61(5):2020-2041.

PMID: 36920708 DOI: 10.1007/s10528-023-10355-3.